|
gptkbp:instanceOf
|
benzodiazepine
sedative-hypnotic drug
|
|
gptkbp:activeIngredient
|
gptkb:secobarbital_sodium
|
|
gptkbp:ATCCode
|
N05CA02
|
|
gptkbp:brand
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:category
|
benzodiazepine
anticonvulsant
central nervous system depressant
hypnotic
|
|
gptkbp:chemicalFormula
|
C12H17N2NaO3
|
|
gptkbp:color
|
red (capsule)
|
|
gptkbp:contraindication
|
porphyria
history of drug abuse
severe respiratory disease
|
|
gptkbp:discoveredBy
|
gptkb:Donalee_L._Tabern
gptkb:Ernest_H._Volwiler
|
|
gptkbp:discoveredIn
|
1934
|
|
gptkbp:eliminationHalfLife
|
15-40 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
gptkb:tablet
capsule
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Seconal Sodium
|
|
gptkbp:legalStatus
|
Schedule II controlled substance (US)
|
|
gptkbp:marketedAs
|
1934
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:otherName
|
gptkb:Seconal
gptkb:secobarbital_sodium
reds
red devil
|
|
gptkbp:overdoseSymptoms
|
death
coma
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:riskFactor
|
addiction
abuse
withdrawal symptoms
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
drowsiness
respiratory depression
dependence
|
|
gptkbp:usedFor
|
treatment of insomnia
preoperative sedation
|
|
gptkbp:usedIn
|
physician-assisted suicide (in some jurisdictions)
euthanasia (in some jurisdictions)
|
|
gptkbp:withdrawn
|
some countries
|
|
gptkbp:bfsParent
|
gptkb:Secobarbital
|
|
gptkbp:bfsLayer
|
7
|